Pancreatic Cancer Research

ResearcherAnhui Medical UniversityActive in the last 2 years

Zihe Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-6518-7119; OpenAlex author ID A5101837529. Sources: OpenAlex.

Their work

Papers
10 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2021: 1 paper · 2022: 4 papers · 2023: none · 2024: 3 papers · 2025: 2 papers

Papers 10

  1. Looking at or beyond the tumor - a systematic review and meta-analysis of quantitative imaging biomarkers predicting pancreatic cancer prognosis. Co-author DOI 10.1007/s00261-025-04919-7↗
  2. Synchronous surgery combined preoperative chemotherapy benefits patients suffering pancreatic ductal adenocarcinoma with liver metastases: a systematic review … First author DOI 10.1038/s41598-025-13811-9↗
  3. Quantitative MR imaging biomarkers for distinguishing inflammatory pancreatic mass and pancreatic cancer-a systematic review and meta-analysis. Co-author DOI 10.1007/s00330-024-10720-9↗
  4. MALAT1 promotes epithelial-mesenchymal transition of pancreatic cancer cells through the miR-141-5p-TGF-ß-TGFBR1/TGFBR2 axis. Co-author DOI 10.1684/ecn.2024.0495↗
  5. Flubendazole presents anti-tumor effects by promoting cell cycle arrest and inhibiting the invadopodia in pancreatic cancer First author DOI 10.21203/rs.3.rs-4570726/v1↗
  6. Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis. Co-author DOI 10.1007/s10238-021-00785-x↗
  7. Long non-coding RNA DSCAM-AS1 promotes pancreatic cancer progression via regulating the miR-136-5p/PBX3 axis. First author DOI 10.1080/21655979.2021.2016326↗
  8. Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single cen… Co-author DOI 10.3389/fonc.2022.966256↗
  9. Prognostic role of the prognostic nutritional index in patients with pancreatic cancer who underwent curative resection without preoperative neoadjuvant treatm… Co-author DOI 10.3389/fsurg.2022.992641↗
  10. EUS-CGN versus EUS-CPN in pancreatic cancer: A qualitative systematic review. First author DOI 10.1097/md.0000000000027103↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pengcheng Zhao · 3 shared papers, 2022–2025 · strength 0.77
  2. Liang Zhu · 2 shared papers, 2024–2025 · strength 0.61
  3. Kang Xue · 2 shared papers, 2024–2025 · strength 0.59
  4. Zuowei Wu · 3 shared papers, 2021–2022 · strength 0.50
  5. Xing Huang · 3 shared papers, 2021–2022 · strength 0.50
  6. Li Mao · 3 shared papers, 2021–2022 · strength 0.50
  7. Xing Huang · 2 shared papers, 2022–2024 · strength 0.43
  8. Weiming Hu · 2 shared papers, 2022–2024 · strength 0.41
  9. Huimin Lu · 2 shared papers, 2022–2024 · strength 0.41
  10. Zhenlu Li · 2 shared papers, 2022 · strength 0.36
  11. Bole Tian · 2 shared papers, 2022 · strength 0.35
  12. Bole Tian · 1 shared paper, 2025 · strength 0.33
  13. Chao Wu · 2 shared papers, 2021–2022 · strength 0.31
  14. Huadan Xue · 1 shared paper, 2024 · strength 0.31
  15. Zhengyu Jin · 1 shared paper, 2024 · strength 0.31
  16. Cheng Ding · 1 shared paper, 2025 · strength 0.30
  17. Xianlin Han · 1 shared paper, 2025 · strength 0.30
  18. Bole Tian · 1 shared paper, 2024 · strength 0.26
  19. Zhenlu Li · 1 shared paper, 2024 · strength 0.24
  20. Weiming Hu · 1 shared paper, 2022 · strength 0.19
  21. Huimin Lü · 1 shared paper, 2022 · strength 0.19
  22. Pengcheng Zhao · 1 shared paper, 2022 · strength 0.16
  23. Li Wang · 1 shared paper, 2022 · strength 0.16
  24. Bole Tian · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.